Changes in Plasma Soluble Receptor for Advanced Glycation End-Products Are Associated with Survival in Patients with Acute Respiratory Distress Syndrome
Authors:
- Matthieu JabaudonMatthieu Jabaudon
- Bruno PereiraBruno Pereira
- Erwan LarocheELErwan Laroche
- Laurence RoszykLRLaurence Roszyk
- Raiko BlondonnetRBRaiko Blondonnet
- Jules AudardJAJules Audard
- Thomas GodetTGThomas Godet
- Emmanuel FutierEFEmmanuel Futier
- Jean-Etienne BazinJBJean-Etienne Bazin
- Vincent SapinVincent Sapin
- Julie A. BastaracheJBJulie A. Bastarache
- Lorraine B. WareLWLorraine B. Ware
Open Access
- 12 May 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (10) , 2076
Abstract
The plasma soluble receptor for advanced glycation end-products (sRAGE) is a marker of lung epithelial injury with prognostic value when measured at baseline in acute respiratory distress syndrome (ARDS). However, whether changes in plasma sRAGE could inform prognosis in ARDS remains unknown. In this secondary analysis of the Lung Imaging for Ventilator Setting in ARDS (LIVE) multicenter randomized controlled trial, which evaluated a personalized ventilation strategy tailored to lung morphology, plasma sRAGE was measured upon study entry (baseline) and on days one, two, three, four and six. The association between changes in plasma sRAGE over time and 90-day survival was evaluated. Higher baseline plasma sRAGE (HR per-one log increment, 1.53; 95% CI, 1.16–2.03; p = 0.003) and an increase in sRAGE over time (HR for each one-log increment in plasma sRAGE per time unit, 1.01; 95% CI, 1.01–1.02; p < 10−3) were both associated with increased 90-day mortality. Each 100-unit increase in the plasma sRAGE level per unit of time increased the risk of death at day 90 by 1% in joint modeling. Plasma sRAGE increased over time when a strategy of maximal alveolar recruitment was applied in patients with focal ARDS. Current findings suggest that the rate of change in plasma sRAGE over time is associated with 90-day survival and could be helpful as a surrogate outcome in ARDS.Keywords
Funding Information
- Direction Générale de l’offre de Soins (Programme Hospitalier de Recherche Clinique Inter-Regional 2013, ANR-13-PRTS-0010)
- Conseil Régional d'Auvergne (Programme Nouveau Chercheur de la Région Auvergne 2013)
- Agence Nationale de la Recherche (ANR-13-PRTS-0010)
- Clinical Center (HL103836, HL135849, HL126176, HL126671)
This publication has 30 references indexed in Scilit:
- Acute Respiratory Distress SyndromeJAMA, 2012
- Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients*Critical Care Medicine, 2011
- Elevated Levels of the Receptor for Advanced Glycation End Products, a Marker of Alveolar Epithelial Type I Cell Injury, Predict Impaired Alveolar Fluid Clearance in Isolated Perfused Human LungsChest, 2009
- Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injuryThorax, 2008
- Plasma Receptor for Advanced Glycation End-products Predicts Duration of ICU Stay and Mechanical Ventilation in Patients After Lung TransplantationThe Journal of Heart and Lung Transplantation, 2007
- Receptor for Advanced Glycation End-Products is a Marker of Type I Cell Injury in Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Alveolar Fluid Clearance Is Impaired in the Majority of Patients with Acute Lung Injury and the Acute Respiratory Distress SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2001
- A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter StudyJAMA, 1993
- A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter studyJAMA, 1993
- Gram-Negative BacteremiaArchives of internal medicine (1960), 1962